Table 3.
IC50 values of the anti-proliferative and cytotoxic effects of compounds 1, 2, and 3 as determined after 48 h treatment of breast cancer MDA-MB-468 and MDA-MB-231 cells, Ewing’s sarcoma SK-N-MC cells, and prostate cancer PC-3 cells by using MTT and CV (crystal violet) assays, respectively.
| IC50 Values (after 48 h Treatment) | Assay | Compound 1 | Compound 2 | Compound 3 |
|---|---|---|---|---|
| MDA-MB-468 (breast cancer) | MTT | >100 µM | 85.9 µM | 41.0 µM |
| CV | >100 µM | 80.0 µM | 47.7 µM | |
| MDA-MB-231 (breast cancer) | MTT | >100 µM | >100 µM | 45.6 µM |
| CV | >100 µM | >100 µM | 49.1 µM | |
| SK-N-MC (Ewing’s sarcoma) | MTT | >100 µM | 71.1 µM | 71.9 µM |
| CV | >100 µM | 56.4 µM | 52.9 µM | |
| PC-3 (prostate cancer) | MTT | >100 µM | >100 µM | >100 µM |
| CV | >100 µM | >100 µM | >100 µM |